{"id":8127,"date":"2023-11-09T07:00:00","date_gmt":"2023-11-09T07:00:00","guid":{"rendered":"https:\/\/www.acarix.com\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/"},"modified":"2024-11-18T19:04:45","modified_gmt":"2024-11-18T19:04:45","slug":"acarix-ab-publ-publishes-interim-report-july-september-2023-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/","title":{"rendered":"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p class=\"mfn-wp-retain\"><strong>Continued momentum in the US and strengthened financing in place<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p class=\"mfn-wp-retain\">We are pleased with the Q3 revenue growth in the US, where we are making significant investments to grow sales via our relatively low-cost hybrid sales model. To further increase the US growth rate, changes are planned in the sales organization. We are currently focused on the 2 Veterans Affairs (VA) accounts in the State of Louisiana, who already purchased CADScor systems, while some other VA&rsquo;s are seeking approvals for an additional budget for CADScor use. We are also making tangible progress with a specific, large IDN while we continue to make progress with developing additional other leads.<\/p>\n<p class=\"mfn-wp-retain\"><em>Extract from Acting CEO Fred Colen&rsquo;s message to the Interim Report.<\/em><\/p>\n<p class=\"mfn-wp-retain\"><strong>Third quarter 2023 compared to the same period 2022<\/strong><\/p>\n<ul>\n<li>Revenue in the third quarter amounted to SEK 1,573 thousand (1,164). Gross profit amounted to SEK 1,292 thousand (921), corresponding to a gross margin of 82% (79%) and an improvement of 3% points compared to the same period in 2022<\/li>\n<li>During the quarter, 14 (14) CADScor&reg;Systems and 1,903 (1,812) patches were sold<\/li>\n<li>Operating expenses amounted to SEK 18,517 thousand (21,653)<\/li>\n<li>Earnings before tax amounted to SEK -17,291 thousand (-21,106)<\/li>\n<li>Net cash flow for the period amounted to SEK -16,705 thousand (-21,218)<\/li>\n<li>Earnings per share amounted to SEK -0.04 (-0.08)<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\"><strong>First nine months 2023 compared to the same period in 2022<\/strong><\/p>\n<ul>\n<li>Revenue during the first nine months of the year amounted to SEK 5,067 thousand (4,169). Gross profit amounted to SEK 4,270 thousand (3,292), corresponding to a gross margin of 84% (79%) and an improvement of 5% points compared to the same period in 2022<\/li>\n<li>During the period, 36 (48) CADScor&reg;Systems and 7,120 (6,252) patches were sold<\/li>\n<li>Operating expenses amounted to SEK 59,825 thousand (57,153)<\/li>\n<li>Earnings before tax amounted to SEK &ndash;55,775 thousand (&ndash;54,372)<\/li>\n<li>Net cash flow amounted to SEK -2,453 thousand (12,372)<\/li>\n<li>Cash and cash equivalents amounted to SEK 9,246 thousand (29,409)<\/li>\n<li>Earnings per share amounted to SEK &ndash;0.13 (&ndash;0.22). No dilutive effects occurred.<\/li>\n<li>The number of shares on the balance sheet date amounts to 452,868,010 (251,972,194)<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\"><strong>Events during the third quarter, 2023<\/strong><\/p>\n<ul>\n<li>On August 28, the company announced the appointment of Dr. Deepak R. Talreja, MD, as new Medical Advisor. With an impressive background in cardiology, Dr. Talreja brings a wealth of knowledge and expertise to Acarix, further strengthening the company&rsquo;s commitment to transforming early cardiac diagnostics through cutting-edge acoustic and AI-based technology.<\/li>\n<li>On August 29, the company announced significant progress in the use of the CADScor System by the Veterans Administration (VA), the largest healthcare provider in the United States. VA Healthcare System in southeastern Louisiana has now approved the inclusion of the CADScor System in its Standard Operating Procedure (SOP) for risk stratification of symptomatic patients with suspected coronary artery disease (CAD). Furthermore, another VA hospital &#8211; Biloxi VA Medical Center (VA Gulf Coast Veterans Healthcare System) has placed first order for CADScor System with associated patches.<\/li>\n<li>On September 4, the company announced the collaboration with Maeva Health, led by Dr. Peter Svalander, CEO, for the launch of the CADScor system in Mauritius and further into the expansive East African market with a population of over 485 million. The partnership with Maeva resulted in a first order for three CADScor systems.<\/li>\n<li>On September 11, the company announced a decision on a rights issue of approximately SEK 54 million, fully guaranteed by, among others, a Danish life science fund.<\/li>\n<li>On September 27, the company announced the first deal in osteopathic medicine in the US market. The initial order for CADScor&reg;System from Legacy Medical LLC, located in the state of Georgia, is another important milestone in the company&rsquo;s ongoing commercialization efforts in the US market.<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\"><strong>Events after September 30, 2023<\/strong><strong><br \/><\/strong><\/p>\n<ul>\n<li>On October 10, the company announced that CEO Helen Ljungdahl Round had been on sick leave for treatment of cancer for an expected period of approximately six months. The Board of Directors has appointed Fred Colen as acting CEO with immediate effect during Helen&rsquo;s sick leave.<\/li>\n<li>On October 20, the company announced the final outcome of the Rights Issue of units, consisting of shares and warrants of series 2024:U1 (TO2) and series 2024:U2 (TO3), with preferential rights for existing shareholders (the &rdquo;Rights Issue&rdquo;), which was completed on October 18, 2023. A total of 67,126,093 units, corresponding to approximately 74.1 percent of the Rights Issue, were subscribed for with and without unit rights. Thus, the guarantors who have provided top guarantees are allotted a total of 23,447,509 units, corresponding to approximately 25.9 percent of the Rights Issue. Through the Rights Issue, Acarix will receive a total of approximately SEK 54.3 million before deduction of costs attributable to the Rights Issue.<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\">Link to the report: <a href=\"https:\/\/www.acarix.com\/for-investors\/financial-reports-and-calendar\" rel=\"noopener\" target=\"_blank\">https:\/\/www.acarix.com\/for-investors\/financial-reports-and-calendar<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-5f6793025012\">\n<p class=\"mfn-wp-retain\"><strong class=\"mfn-heading-1\">For more information contact:<\/strong><br \/>Fred Colen, acting CEO, email <a href=\"mailto:helen.round@acarix.com\" rel=\"noopener\" target=\"_blank\">fred.colen@acarix.com<\/a>&nbsp;<br \/>Christian Lindholm, CFO, phone +46&nbsp;705 118333, email <a href=\"mailto:christian.lindholm@acarix.com\" rel=\"noopener\" target=\"_blank\">christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-ddf9d1ef3849\">\n<p class=\"mfn-wp-retain\"><strong class=\"mfn-heading-1\">About Acarix<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor&reg;System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, <a href=\"mailto:certifiedadviser@redeye.se\" rel=\"noopener\" target=\"_blank\">certifiedadviser@penser.se<\/a>) is Certified Advisor of Acarix. For more information, please visit <a href=\"http:\/\/www.acarix.com\" rel=\"noopener\" target=\"_blank\">www.acarix.com<\/a>.&nbsp;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p class=\"mfn-wp-retain\"><strong class=\"mfn-heading-1\">Attachments<\/strong><br \/><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/f86a0b1b-5908-4398-be98-a24de5b7dbe6\/acarix-q3-2023-eng-final.pdf\" rel=\"noopener\" target=\"_blank\">Acarix Q3 2023 Eng Final<\/a><\/p>\n<\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-primary\"><a class=\"mfn-attachment-link\" href=\"https:\/\/storage.mfn.se\/f86a0b1b-5908-4398-be98-a24de5b7dbe6\/acarix-q3-2023-eng-final.pdf\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/f86a0b1b-5908-4398-be98-a24de5b7dbe6\/acarix-q3-2023-eng-final.pdf?type=jpg\"><\/span>Acarix Q3 2023 Eng Final<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Continued momentum in the US and strengthened financing in place We are pleased with the Q3 revenue growth in the<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[143,157,140,154,139,160,148,155],"tags":[],"class_list":["post-8127","post","type-post","status-publish","format-standard","hentry","category-mfn-lang-en","category-mfn-report-interim","category-mfn-type-ir","category-mfn-regulatory-listing","category-mfn","category-mfn-report-interim-q3","category-mfn-regulatory","category-mfn-report"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acarix AB (publ) publishes Interim Report, July \u2013 September 2023 - Acarix<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023 - Acarix\" \/>\n<meta property=\"og:description\" content=\"Continued momentum in the US and strengthened financing in place We are pleased with the Q3 revenue growth in the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Acarix\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-09T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-18T19:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/d.ptpl.dev\/acarix\/wp-content\/uploads\/2026\/02\/Acarix_web_image.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"673\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"acarix\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"acarix\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/\"},\"author\":{\"name\":\"acarix\",\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/#\\\/schema\\\/person\\\/dac8bcb35fc08033de2c787d232971b5\"},\"headline\":\"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023\",\"datePublished\":\"2023-11-09T07:00:00+00:00\",\"dateModified\":\"2024-11-18T19:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/\"},\"wordCount\":933,\"articleSection\":[\"English\",\"Interim\",\"IR\",\"Listing Regulation\",\"News\",\"Q3\",\"Regulatory\",\"Report\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/\",\"url\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/\",\"name\":\"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023 - Acarix\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/#website\"},\"datePublished\":\"2023-11-09T07:00:00+00:00\",\"dateModified\":\"2024-11-18T19:04:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/#\\\/schema\\\/person\\\/dac8bcb35fc08033de2c787d232971b5\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/#website\",\"url\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/\",\"name\":\"Acarix\",\"description\":\"CADScor\u00aeSystem\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/#\\\/schema\\\/person\\\/dac8bcb35fc08033de2c787d232971b5\",\"name\":\"acarix\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d1673e9c4b856fa2627a73e477d2d10d47c79d882f69fa533eaf7143a571f6f2?s=96&r=g&d=https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/wp-content\\\/plugins\\\/userswp\\\/assets\\\/images\\\/no_profile.png\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d1673e9c4b856fa2627a73e477d2d10d47c79d882f69fa533eaf7143a571f6f2?s=96&r=g&d=https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/wp-content\\\/plugins\\\/userswp\\\/assets\\\/images\\\/no_profile.png\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d1673e9c4b856fa2627a73e477d2d10d47c79d882f69fa533eaf7143a571f6f2?s=96&r=g&d=https:\\\/\\\/d.ptpl.dev\\\/acarix\\\/wp-content\\\/plugins\\\/userswp\\\/assets\\\/images\\\/no_profile.png\",\"caption\":\"acarix\"},\"sameAs\":[\"https:\\\/\\\/www.acarix.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023 - Acarix","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023 - Acarix","og_description":"Continued momentum in the US and strengthened financing in place We are pleased with the Q3 revenue growth in the","og_url":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/","og_site_name":"Acarix","article_published_time":"2023-11-09T07:00:00+00:00","article_modified_time":"2024-11-18T19:04:45+00:00","og_image":[{"width":1200,"height":673,"url":"https:\/\/d.ptpl.dev\/acarix\/wp-content\/uploads\/2026\/02\/Acarix_web_image.webp","type":"image\/webp"}],"author":"acarix","twitter_card":"summary_large_image","twitter_misc":{"Written by":"acarix","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/#article","isPartOf":{"@id":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/"},"author":{"name":"acarix","@id":"https:\/\/d.ptpl.dev\/acarix\/#\/schema\/person\/dac8bcb35fc08033de2c787d232971b5"},"headline":"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023","datePublished":"2023-11-09T07:00:00+00:00","dateModified":"2024-11-18T19:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/"},"wordCount":933,"articleSection":["English","Interim","IR","Listing Regulation","News","Q3","Regulatory","Report"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/","url":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/","name":"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023 - Acarix","isPartOf":{"@id":"https:\/\/d.ptpl.dev\/acarix\/#website"},"datePublished":"2023-11-09T07:00:00+00:00","dateModified":"2024-11-18T19:04:45+00:00","author":{"@id":"https:\/\/d.ptpl.dev\/acarix\/#\/schema\/person\/dac8bcb35fc08033de2c787d232971b5"},"breadcrumb":{"@id":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/d.ptpl.dev\/acarix\/acarix-ab-publ-publishes-interim-report-july-september-2023-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d.ptpl.dev\/acarix\/"},{"@type":"ListItem","position":2,"name":"Acarix AB (publ) publishes Interim Report, July \u2013 September 2023"}]},{"@type":"WebSite","@id":"https:\/\/d.ptpl.dev\/acarix\/#website","url":"https:\/\/d.ptpl.dev\/acarix\/","name":"Acarix","description":"CADScor\u00aeSystem","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d.ptpl.dev\/acarix\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/d.ptpl.dev\/acarix\/#\/schema\/person\/dac8bcb35fc08033de2c787d232971b5","name":"acarix","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d1673e9c4b856fa2627a73e477d2d10d47c79d882f69fa533eaf7143a571f6f2?s=96&r=g&d=https:\/\/d.ptpl.dev\/acarix\/wp-content\/plugins\/userswp\/assets\/images\/no_profile.png","url":"https:\/\/secure.gravatar.com\/avatar\/d1673e9c4b856fa2627a73e477d2d10d47c79d882f69fa533eaf7143a571f6f2?s=96&r=g&d=https:\/\/d.ptpl.dev\/acarix\/wp-content\/plugins\/userswp\/assets\/images\/no_profile.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d1673e9c4b856fa2627a73e477d2d10d47c79d882f69fa533eaf7143a571f6f2?s=96&r=g&d=https:\/\/d.ptpl.dev\/acarix\/wp-content\/plugins\/userswp\/assets\/images\/no_profile.png","caption":"acarix"},"sameAs":["https:\/\/www.acarix.com"]}]}},"_links":{"self":[{"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/posts\/8127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/comments?post=8127"}],"version-history":[{"count":0,"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/posts\/8127\/revisions"}],"wp:attachment":[{"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/media?parent=8127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/categories?post=8127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d.ptpl.dev\/acarix\/wp-json\/wp\/v2\/tags?post=8127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}